Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation

British Journal of Cancer

Volumn 75, Issue 4, 1997, Pages 528-536

  El Mahdani, N ^a   Vaillant, J C ^a   Guiguet, M ^a   Prevot S ^a   Bertrand, V ^a   Bernard, C ^a   Parc, R ^a   Bereziat G ^a   Hermelin, B ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Colorectal cancer; Inactivation; mRNA overexpression; Mutation; p53

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ADULT; ARTICLE; CANCER GENETICS; COLORECTAL CANCER; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031045324     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.92     Document Type: Article

References (77)

1. Agoff SN, Hou J, Linzer DIH and Wu B (1993) Regulation of the human hsp 70 promoter by p53. Science 259; 84-87
2. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S and Hakama M (1994) Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70: 293-296
3. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JKV, Hamilton S and Vogelstein B (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis Cancer Res 50: 7717-7722
4. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, Leigh JM, Purkis T, MacGeoch C, Spurr NK, Bartek J, Vojtesek B, Picksley SM, and Lane DP (1992) Abnormal expression of wild-type p53 protein in normal cells of a cancer family patient. Lancet 340: 259-263
5. Battifora H (1994) p53 immunohistochemistry: a word of caution. Hum Pathol 25: 435-437
6. Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP and Santibanez-Koref MF (1994) Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 70: 1176-1181
7. Boccuzzi A, Terzolo M, Leonardo E, Cappia S, Tappero G, Paccotti P and Angeli A (1995) High frequency of p53 expression in colorectal adenomatous polyps. Anticancer Res 15: 1407-1410
8. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ and Lee AKC (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Instit 86: 681-687
9. Castresana JS, Rubio MP, Vazquez JJ, Idoate M, Sober AJ, Scizinger BR and Barnhill RL (1993) Lack of allelic deletion and point mutation as mechanisms of p53 inactivation in human malignant melanoma. Int J Cancer 55:562-565
10. Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR-I gene by ras and p53. Science 255: 459-462
11. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Willye AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852
12. Deffie A, Wu II, Reinke V and Lozano G (1993) The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13: 3415-3423
13. Delattre O, Law DJ, Remvikos Y Sastre X, Feinberg AP, Olschwang S, Melot T, Salmon RJ, Validire P and Thomas G (1989) Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 12: 353-355
14. Dix B, Robbins P, Carrello S, House A and Iacopetta B (1994) Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70: 585-590
15. Dulic V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ and Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023
16. El-Deiry WS, Kern SE, Pietanpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53 Nature Genet 1: 45-49
17. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAFL, a potential mediator of p53 tumor suppression. Cell 75: 817-825
18. Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giachetti S, Marty M and Calvo F (1994) p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69: 1145-1150
19. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R and Prives C (1992) Wild-type p53 activates transcription in vitro. Nature 358: 83-86
20. Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
21. Fritsch EF. Sambrook J and Maniatis T (1989) Molecular Cloning. A Laboratory Manual, 2nd edn. pp 916-919 Cold Spring Harbor Laboratory Press: Cold Spring Harbor. NY
22. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA and Roth GJ (1994) Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458-1459
23. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871
24. Ginsberg D, Mechta F, Yaniv M and Oren M (1991) Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88: 9979-9983
25. Gope M L, Chun M and Gope R (1991) Comparative study of the expression of Rb and p53 genes in human colorectal cancers, colon carcinoma cell lines and synchronized human fibroblasts. Mol Cell Biol 107: 55-63
26. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor supressor gene: clues to etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
27. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42-48
28. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ (1993) The p21 Cdk interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
29. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
30. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R and Takahashi T (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1-4
31. Juven T, Barak Y, Zauberman A, George DL and Oren M (1993) Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416
32. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
33. Kastan MB, Zhan Q, El-Diery WS, Carrier F Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597
34. Kennedy SM, MacGeogh C, Jaffe R and Spurr NK (1994) Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 25: 438-442
35. Kern SE, Fearon ER, Tersmette KWF, Enterline JP, Leffert M, Nakamura Y, White R, Vogelstein B and Hamilton S R (1989) Allelic loss in colorectal cancer. JAMA 261: 3099-3103
36. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C and Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711
37. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler W and Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830
38. Kinzler KW and Vogelstein B (1994) Clinical implications of basic research: cancer therapy meets p53. N Engl J Med 131: 49-50
39. Kupryjanczyk I, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA and Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961-4965
40. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
41. Lang FF, Miller DC, Pisharody S Koslow M and Newcomb E W (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9: 949-954
42. Lee JM and Bemstein A (1993) p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742-5746
43. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-455
44. Liu X, Miller CW, Koeffler PH and Berk AJ (1993) The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol 13: 3291-3300
45. Lothe RA, Fossli T, Danielsen HE, Stenwig AE, Nesland JM, Gallie B and Borressen AL (1992) Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J Natl Cancer Inst 84: 1100-1108
46. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849
47. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
48. Marklin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, Kassel J, Cryka MA, Bischoff FZ, Tainsky MA and Friend SH (1990) Germ-line p53 mutations in a familial syndrome of breast cancer, sarcoma and other neoplasms. Science 250: 1233-1238
49. Milner J, Medcalf AE and Cook CA (1991) Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol 11: 12-19
50. Moberg KH, Tyndall WA and Hall DJ (1992) Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line. J Cell Biol 49: 208-215
51. Moll UM, Riou G and Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262-7266
52. Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83
53. Oliner JD, Pietenpol JA, Thiagaligam SS, Gyuris J, Kinzler KW and Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumor supressor p53. Nature 362: 857-860
54. Papathanasiou MA, Kerr NC, Robbins JH, McBride OW, Alamo I Jr, Barrett SF, Hickson ID and Fornace AJ Jr (1991) Induction by ionizing radiation of the gadd-45 gene in cultured human cells: lack of mediation by protein kinase C. Mol Cell Biol 11: 1009-1016
55. Peng HQ, Hogg D, Malkin D, Bailey D, Gallu BL, Bultal M, Jerrett M, Buchanan J and Cross PE (1993) Mutation of the p53 gene did not occur in testis cancer. Cancer Res 53: 3574-3578
56. Pignatelli M, Stamp GW, Kafiri G, Lane D and Bodmer WF (1992) Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 50: 683-688
57. Rideout WM III, Coetzee GA, Olumi AF and Jones PA (1990) 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249: 1288-1290
58. Santhanam U, Ray A and Sehgal PB (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88: 7605-7609
59. Shiio Y, Yamamoto T and Yamaguchi N (1992) Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci USA 89: 5206-5210
60. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK and Hittelman WN (1994) Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 321-326
61. Srivastava S, Zou Z, Pirollo K, Blattner W and Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-749
62. Starzynska T, Bromley M, Ghosh A and Stem PL (1992) Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66: 558-562
63. Subler MA, Martin DW and Deb S (1992) Inhibition of viral and cellular promoters by human wild type p53. J Virol 66: 4757-4762
64. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T and Nordenskjöld B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369-1373
65. Sved J and Bird A (1990) The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc Natl Acad Sci USA 87: 4692-4696
66. Thorlacius S, Börresen AL and Eyfjörd JE (1993) Somatic p53 mutations in human breast carcinomas in an icelandic population: a prognostic factor. Cancer Res 53: 1637-1641
67. 1160. Science 267: 100-103
68. Tominaga O, Hamelin R, Trouvat V, Salmon RJ, Lesec G, Thomas G and Remvikos Y (1993) Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene 8: 2653-2658
69. Tornaletti S and Pfeifer GP (1995) Complete and tissue-independent methylation of CpG sites in the p53 gene: implication for mutations in human cancers. Oncogene 8: 1493-1499
70. Vogelstein B (1990) A deadly inheritance. Nature 348: 681-682
71. Waga S, Hannon GJ, Beach D and Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578
72. Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T and Ishizaki K (1993) Loss of 17p. mutation of the p53 gene and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 53: 846-850
73. Weintraub H, Hauschka S and Tapscott S J (1991) The MCK enhancer contains a p53 responsive element. Proc Natl Acad Sci USA 88: 4570-4571
74. Wolkmann M, Holmann WJ, Müller M, Räth U, Otto G, Zentgraf H and Galle PR (1994) p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 9: 195-204
75. Yamaguchi A, Kurosaka Y, Fushida S, Kano M, Yonemura Y, Miwa K and Miyazaki I (1992) Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70: 2778-2784
76. Zambetti GP and Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-863
77. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charutonowiez E, Guillem JG, Cordon-Cardo C and Cohen AF (1994) p53 nuclear overexpression: an independent predictor of survival in lymphnode-positive colorectal cancer patients. J Clin Oncol 12: 2043-2050